Search Results

Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced completion of enrollment and initial dosing in the Phase 1 portion of its adaptive Phase 1/2 clinical trial, IMCY-MS-001.

Imcyse today announced completion of patient enrollment in its Phase 2 IMPACT ( IM CY-0098 P roof of AC tion in T ype 1 Diabetes) trial of its lead product candidate IMCY-0098, a proinsulin-derived Imotope™ engineered to halt the progression and prevent early-onset Type 1 diabetes (T1D).

Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, announced today that Denis Bedoret, M.D., Ph.D., Chief Executive Officer of Imcyse, will participate in a corporate presentation at the Oppenheimer 32nd Annual Healthcare Conference.

Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, announced the appointment of Gene Mack, MBA, as Chief Financial Officer.

Imcyse today announced the first patient has been dosed in the adaptive Phase 1/2 clinical trial evaluating ImotopeTM IMCY-0141 in patients with relapsing-remitting multiple sclerosis (RRMS).

Imcyse today reported positive biomarker data from a planned interim analysis of its Phase 2 study, IMCY-0098 Proof of ACtion in Type 1 Diabetes (T1D) (IMPACT), evaluating the Company’s lead candidate IMCY-0098, a proinsulin-derived ImotopeTM engineered to treat and prevent T1D.

Imcyse and Pfizer to collaborate to develop Imotope TM candidates to potentially treat Rheumatoid Arthritis Pfizer to lead clinical development and commercialization activities

Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, announced that it has concluded a Series B extension financing round, raising EUR 21.3 million.

Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the first patients treatment in the IM CY-0098 proof of Action in T ype 1 Diabetes (T1D) (IMPACT) study with IMCY-0098.

Proceeds will facilitate clinical development of Imcyse’s technology in type 1 diabetes, multiple sclerosis and other indications